COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: the patients with diagnosis of COVID-19 will be treated by tablet Montelukast 10 mg. This treatment will be in addition to standard therapies for these patients. Th
Sponsors
Abidi Pharmaceutical company
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: Every patient with diagnosis of COVID-19 Mild, moderate and severe stage of the disease
Exclusion criteria
Exclusion criteria: No complete consent and compliace of the patient for study Follow up of the patient not be possible The age below 15 years old Rifampin and Phenobarbital consumers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Discontinuation of fever. Timepoint: Daily till 14 days. Method of measurement: Measurement of temperature by digital infrared thermometer, and the O2 saturation by pulseoximeter.;Decreased Respiratory Rate. Timepoint: Daily till 14 days. Method of measurement: Measurement of fever by a termometer, and O2 saturation by pulse Oximetery.;Decreased Cough. Timepoint: Daily till 14 days. Method of measurement: Body temperature by thermometer, O2 sat by pulseoximetery.;Evaluation of blood O2 Saturation. Timepoint: Daily till 14 days. Method of measurement: Physician evaluation by Puls oxymetery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of the patient with diagnosis of COVID-19 infection. Timepoint: Daily till 14 days. Method of measurement: Evaluation by Physician. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMorteza Pourahmad
Esfahan University of Medical Sciences
Outcome results
None listed